Last $51.59 USD
Change Today 0.00 / 0.00%
Volume 0.0
CHGCY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
Frankfurt
As of 8:10 PM 04/7/14 All times are local (Market data is delayed by at least 15 minutes).

chugai pharmaceutic-unsp adr (CHGCY) Snapshot

Open
$51.59
Previous Close
$51.59
Day High
$51.59
Day Low
$51.59
52 Week High
04/7/14 - $51.59
52 Week Low
01/6/14 - $44.08
Market Cap
14.4B
Average Volume 10 Days
10.5
EPS TTM
--
Shares Outstanding
279.8M
EX-Date
12/26/13
P/E TM
--
Dividend
$0.90
Dividend Yield
1.83%
Current Stock Chart for CHUGAI PHARMACEUTIC-UNSP ADR (CHGCY)

Related News

No related news articles were found.

chugai pharmaceutic-unsp adr (CHGCY) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutic-unsp adr (CHGCY) Details

Chugai Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Japan and internationally. Its principal products in oncology include Kytril, Femara, Tarceva, Xeloda, Neutrogin, Rituxan, Herceptin, and Avastin; bone and joint disease products comprise Edirol, Alfarol, Suvenyl, Evista, and Actemra; and renal disease products consist of Renagel, Oxarol, Epogin, and Mircera. The company also provides products for chronic hepatitis C, which include Copegus, CellCept, Pegasys, Sigmart, and Tamiflu. In addition, it has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, and other diseases. Chugai Pharmaceutical Co., Ltd. has a strategic alliance with Roche; and co-development and co-marketing agreement with Taisho Pharmaceutical Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

6,872 Employees
Last Reported Date: 03/27/14
Founded in 1925

chugai pharmaceutic-unsp adr (CHGCY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

chugai pharmaceutic-unsp adr (CHGCY) Key Developments

Chugai Pharmaceutical Co. Ltd Files Zelboraf for Melanoma in Japan

Chugai Pharmaceutical Co. Ltd. has announced the filing of a new drug application in Japan for Zelboraf (vemurafenib) as a treatment for BRAFV600 mutation-positive melanoma.

Chugai Pharmaceutical Co. Ltd. Presents at The 8th Annual Daiwa Investment Conference Tokyo 2014, Mar-03-2014

Chugai Pharmaceutical Co. Ltd. Presents at The 8th Annual Daiwa Investment Conference Tokyo 2014, Mar-03-2014 . Venue: The Prince Park Tower Tokyo, 4-8-1, Shibakoen, Minato-ku, Tokyo 105-8563, Japan.

Chugai Pharmaceutical Co., Ltd. Announces Management Changes, Effective March 27, 2014, March 31, 2014 and April 1, 2014

Chugai Pharmaceutical Co. Ltd. has announced the appointment of Yutaka Tanaka, currently Senior Vice President, Head of Project & Lifecycle management unit, In Charge of Research, Clinical Development and Medical Affairs, as the new Director, Executive Vice President, Head of Project & Lifecycle management unit, In Charge of Research, Clinical Development and Medical Affairs, effective March 27, 2014. The appointment of Franz B. Humer as a Director is subject to approval at the 103rd Annual General Meeting of Shareholders, which is scheduled to be convened on March 27, 2014. Tatsumi Yamazaki (currently Director, Deputy President) is scheduled to retire from the Director, Deputy President and is going to take the role of Distinguished Advisor as of March 27, 2014. William M. Burns (currently Director) is scheduled to retire from the Director as of March 27, 2014. The company has announced the appointment of Shinya Unno, currently Senior Vice President, General Manager of Corporate Planning Dept., In Charge Of Human Resources, Supervisory Div., General Affairs And Secretarial, as the new Senior Vice President, General Manager of Corporate Planning Dept., in Charge of Human Resources, Supervisory Div., General Affairs, Secretarial And Legal, effective April 1, 2014. In addition, the company has appointed Junichi Ebihara, currently full-time Senior Advisor, as the new Vice President, General Manager of Legal Dept., effective April 1, 2014. Naotaka Nakamura (currently Executive Vice President) and Fumihiko Kamoshida (currently Senior Vice President) are scheduled to retire from the Executive Vice President and the Senior Vice President respectively, as of March 31, 2014. Junichi Ebihara is going to take the role of Full-time Senior Advisor as of February 1, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CHGCY:US $51.59 USD 0.00

CHGCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $115.46 USD -0.08
Novartis AG SFr.74.70 CHF +0.35
View Industry Companies
 

Industry Analysis

CHGCY

Industry Average

Valuation CHGCY Industry Range
Price/Earnings 28.1x
Price/Sales 3.4x
Price/Book 2.5x
Price/Cash Flow 28.8x
TEV/Sales 2.9x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHUGAI PHARMACEUTIC-UNSP ADR, please visit www.chugai-pharm.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.